DiaMedica Therapeutics Inc (DMAC NASDAQ) stock market data APIs
$5.9555
0.78(15.1%)
as of March 18, 2025
DiaMedica Therapeutics Inc Financial Data Overview
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Prev. Close
5.1778
Open
5.9555
High
5.9555
Low
5.1522
52 wk Range
2.14-6.8184
Market Cap
223 M
Shares Outstanding
42 761 K
EPS
-0.18
Beta
1.519
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get DiaMedica Therapeutics Inc data using free add-ons & libraries
Get DiaMedica Therapeutics Inc Fundamental Data
DiaMedica Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -24 074 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-17
- EPS/Forecast: -0.1725
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
DiaMedica Therapeutics Inc News
New
Billionaire Lee Cooperman’s 10 Stock Picks with Huge Upside Potential
In this article, we discuss billionaire Lee Cooperman's 10 stock picks with huge upside potential. To skip the details of Mr. Cooperman’s life and investment strategy, go directly to Billionaire Lee...
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
MINNEAPOLIS, July 18, 2023--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, t...
DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
MINNEAPOLIS, June 26, 2023--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders an...
DiaMedica Therapeutics Announces $37.5 Million Private Placement
MINNEAPOLIS, June 21, 2023--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders an...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
